Krystal Biotech

Forecast & Rating12 analysts currently cover Krystal Biotech, with about 91.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $395.44, about 26.9% upside from the current price of $311.50. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 96.2% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Krystal Biotech closely still see room for the stock to rise. Data as of Oct 21, 2026; for reference only and not investment advice.